Medium- and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial

Markos Klonizakis, Anil Gumber, Emma McIntosh, Leonie S Brose, Markos Klonizakis, Anil Gumber, Emma McIntosh, Leonie S Brose

Abstract

Background: Smoking is a major risk factor for cardiovascular disease and smoking cessation reduces excess risk. E-cigarettes are popular for smoking cessation but there is little evidence on their cardiovascular health effect. Our objective was to compare the medium- and longer-term cardiovascular effects in smokers attempting to quit smoking using e-cigarettes with or without nicotine or prescription nicotine replacement therapy (NRT).

Methods: This was a single-center, pragmatic three-arm randomized (1:1:1) controlled trial, which recruited adult smokers (≥ 10 cigarettes/day), who were willing to attempt to stop smoking with support (n = 248). Participants were randomized to receive behavioral support with either (a) e-cigarettes with 18 mg/ml nicotine, (b) e-cigarettes without nicotine, and (c) NRT. Flow-mediated dilation (%FMD) and peak cutaneous vascular conductance (CVCmax) responses to acetylcholine (ACh) and sodium nitroprusside (SNP), mean arterial pressure (MAP), and other outcomes were recorded at baseline, 3, and 6 months after stopping smoking. Data were analyzed using generalized estimating equations (GEE).

Results: At 3- and 6-month follow-up, %FMD showed an improvement over baseline in all three groups (e.g., p < 0.0001 at 6 months). Similarly, ACh, SNP, and MAP improved significantly over baseline in all groups both at 3 and 6 months (e.g., ACh: p = 0.004, at 6 months).

Conclusions: Smokers attempting to quit experienced positive cardiovascular impact after both a 3- and 6-month period. None of the groups (i.e., nicotine-containing and nicotine-free e-cigarettes or NRT) offered superior cardiovascular benefits to the others.

Trial registration: ClinicalTrials.gov NCT03061253 . Registered on 17 February 2017.

Keywords: CVD; Nicotine replacement therapy; Smoking cessation; Vaping; Vascular function.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart of the study population
Fig. 2
Fig. 2
Central illustration: Changes from baseline to follow-up by treatment arm in (A): Flow mediated dilation (%FMD); (B): Peak cutaneous vascular conductance responses to acetylcholine (ACh); (C):Peak cutaneous vascular conductance responses to sodium nitroprusside (SNP); (D): Mean arterial pressure (MAP)

References

    1. GBD Tobacco Collaborators Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017 doi: 10.1016/S0140-6736(17)30819-X.
    1. Office for National Statistics. Adult smoking habits in the UK: 2019. 2020. .
    1. NHS Digital. Statistics on Smoking England 2018. 2018. .
    1. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Centers for Disease Control and Prevention (US). 2010.
    1. Office on Smoking and Health (US). The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Publications and Reports of the Surgeon General. 2006.
    1. U.S. Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2020.
    1. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016 doi: 10.1002/14651858.CD008286.pub.
    1. Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, Fanshawe TR. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2019 doi: 10.1002/14651858.CD009670.pub.
    1. Brose LS, West R, McDermott MS, Fidler JA, Croghan E, McEwen A. What makes for an effective stop-smoking service? Thorax. 2011;66(10):924–926. doi: 10.1136/thoraxjnl-2011-200251.
    1. Jackson SE, McGowan JA, Ubhi HK, et al. Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation. Addiction. 2019 doi: 10.1111/add.14549.
    1. Action on Smoking and Health (ASH) and Cancer Research UK (CRUK). Many Ways Forward: Stop smoking services and tobacco control work in English local authorities. 2020. .
    1. McNeill A, Brose LS, Calder R, Simonavicius E, Robson D. Vaping in England: an evidence update including vaping for smoking cessation, February 2021. A report commissioned by Public Health England. Public Health England. 2021.
    1. Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2021 doi: 10.1002/14651858.CD010216.pub5.
    1. Jackson SE, Kotz D, West R, Brown J. Moderators of real-world effectiveness of smoking cessation aids: a population study. Addiction. 2019 doi: 10.1111/add.14656.
    1. Beard E, West R, Michie S, Brown J. Association of prevalence of electronic cigarette use with smoking cessation and cigarette consumption in England: a time-series analysis between, 2006 and 2017. Addiction. 2020 doi: 10.1111/add.14851.
    1. MacDonald A, Middlekauf HR. Electronic cigarettes and cardiovascular health: what do we know so far? Vasc Health Risk Manag. 2019;15:159–174. doi: 10.2147/VHRM.S175970.
    1. Tarran R, Barr RG, Benowitz NL, et al. E-Cigarettes and Cardiopulmonary Health Function (Oxf) 2021 doi: 10.1093/function/zqab004.
    1. Kennedy CD, van Schalkwyk MCI, McKee M, Pisinger C. The cardiovascular effects of electronic cigarettes: A systematic review of experimental studies. Prev Med. 2019 doi: 10.1016/j.ypmed.2019.105770.
    1. Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol. 2017 doi: 10.1038/nrcardio.2017.36.
    1. George J, Hussain M, Vadiveloo T, et al. Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. J Am Coll Cardiol. 2019 doi: 10.1016/j.jacc.2019.09.067.
    1. Klonizakis M, Gumber A, McIntosh E, Brose LS. Short-Term Cardiovascular Effects of E-Cigarettes in Adults Making a Stop-Smoking Attempt: A Randomized Controlled Trial. Biology (Basel) 2021 doi: 10.3390/biology10111208.
    1. Klonizakis M, Crank H, Gumber A, Brose LS. Smokers making a quit attempt using e-cigarettes with or without nicotine or prescription nicotine replacement therapy: Impact on cardiovascular function (ISME-NRT) - a study protocol. BMC Public Health. 2017 doi: 10.1186/s12889-017-4206-y.
    1. The National Centre for Smoking Cessation and Training (NCSCT). Standard Treatment Programme - A guide to providing behavioural support for smoking cessation. NCSCT, . 2014.
    1. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. MSSE. 2003 doi: 10.1249/01.MSS.0000078924.61453.FB.
    1. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014 doi: 10.1161/ATVBAHA.113.300156.
    1. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 doi: 10.1016/s0735-1097(01)01746-6.
    1. Klonizakis M, Winter E. Effects of arm-cranking exercise in cutaneous microcirculation in older, sedentary people. Microvas Res. 2011 doi: 10.1016/j.mvr.2011.01.008.
    1. Tew GA, Gumber A, McIntosh E, et al. Effects of supervised exercise training on lower-limb cutaneous microvascular reactivity in adults with venous ulcers. Eur J Appl Physiol. 2018 doi: 10.1007/s00421-017-3772-0.
    1. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011 doi: 10.1007/s11136-011-9903-x.
    1. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009 doi: 10.1136/bmj.b2584.
    1. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003 doi: 10.1016/s0091-7435(03)00110-5.
    1. Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. 2013 doi: 10.4097/kjae.2013.64.5.402.
    1. Twisk J, Bosman L, Hoekstra T, Rijnhart J, Welten M, Heymans M. Different ways to estimate treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018 doi: 10.1016/j.conctc.2018.03.008.
    1. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005 doi: 10.1111/j.1360-0443.2004.00995.x.
    1. Curtis LA, Burns A. Unit Costs of Health & Social Care 2020. Personal Social Services Research Unit, University of Kent Canterbury, UK. 2020. 185 pp. ISBN 978-1-911353-12-6
    1. Fearon IM, Phillips G, Carr T, Taylor M, Breheny D, Faux SP. The Role of Oxidative Stress in Smoking-Related Diseases. Mini Rev Org Chem. 2011;8(4):360–371. doi: 10.2174/157019311797440317.
    1. Carnevale R, Sciarretta S, Violi F, et al. Acute Impact of Tobacco vs Electronic Cigarette Smoking on Oxidative Stress and Vascular Function. Chest. 2016;150(3):606–612. doi: 10.1016/j.chest.2016.04.012.
    1. Fetterman JL, Keith RJ, Palmisano JN, et al. Alterations in Vascular Function Associated With the Use of Combustible and Electronic Cigarettes. J Am Heart Assoc. 2020;9(9):e014570. doi: 10.1161/JAHA.119.014570.
    1. Starke RM, Ali MS, Jabbour PM, et al. Cigarette smoke modulates vascular smooth muscle phenotype: implications for carotid and cerebrovascular disease. PLoS ONE. 2013 doi: 10.1371/journal.pone.0071954.
    1. Quinn U, Tomlinson LA, Cockcroft JR. Arterial stiffness. JRSM. Cardiovasc Dis. 2012 doi: 10.1258/cvd.2012.012024.
    1. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009 doi: 10.1161/CIRCULATIONAHA.109.864801.
    1. Black MA, Cable NT, Thijssen DH, Green DJ. Impact of age, sex, and exercise on brachial artery flow-mediated dilatation. Am J Physiol Heart Circ Physiol. 2009 doi: 10.1152/ajpheart.00226.2009.
    1. Kisch T, Helmke A, Schleusser S, et al. Improvement of cutaneous microcirculation by cold atmospheric plasma (CAP): Results of a controlled, prospective cohort study. Microvas Res. 2016 doi: 10.1016/j.mvr.2015.12.002.
    1. Jones G, McIntosh E, Brose LS, Klonizakis M. Participant Experiences of a Quit Smoking Attempt Through Either Nicotine Replacement Therapy (NRT) Methods or the Use of an E-cigarette. J Addict Med. 2022;16(3): 272–77. 10.1097/ADM.0000000000000881.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅